Collectively, we conclude that IL-33 catered by Cxcl13-Cre+ FSCs to CD8+ T cells in the TME sustains T cell effector differentiation and prevents T cell exhaustion, hence enabling curative melanoma treatment by LCMV-based viral vectors. The gene discussed is CXCL13; the disease is melanoma.